New Study Shows AML Ages Immune Cells, Leading to Poor Treatment Response
Published on in CHOP News
A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.
Relapsed Leukemia and Lymphoma Program News and Updates
1 - 10 of 41
CHOP Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing
Published on in CHOP News
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
CHOP Brings Together Experts to Discuss Precision Medicine in Pediatric Cancer Care
Published on in CHOP News
More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.
CHOP-Led Study Finds Bortezomib Improves Survival in Children with Newly Diagnosed T-Cell Lymphoblastic Lymphoma
Published on in CHOP News
In a COG trial, CHOP researchers found adding bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).
CHOP Researchers Develop Humanized CAR T-Cell Therapy that Shows Potential for Patients with Relapsed B-ALL
Published on in CHOP News
The treatment modifies a domain in the CAR that targets CD19, making it look more human and therefore less likely to be rejected by patients.
Study Shows Benefit of Blinatumomab for High-Risk Relapsed B-ALL
Published on in CHOP News
A new study involving CHOP researchers show blinatumomab is less toxic and as good or better than chemotherapy for high-risk relapsed B-ALL.
AML Immunotherapy Trial Opens
Published on in Oncology Update
CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.
Immunotherapy: What’s Next for CAR-T Therapy
Published on in Oncology Update, Cancer Connections
Trials of more game-changing cell therapies for pediatric cancer and other diseases are underway or on the horizon at Children's Hospital of Philadelphia.
Humanized CD19: CAR-T Immunotherapy for First Relapse of ALL in Down Syndrome Patient
Published on in Cancer Connections
An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.
CAR T-cell Therapy Hailed as Transformative in Pediatric Medicine
Published on in CHOP News
CHOP’s clinical and research teams aggressively pursue options in the field of personalized, cellular gene therapies.